Table 2. Summary results of bivariate model analysis and univariable/multivariable meta-regression.
| Bivariate model analysis | |||||||
| Sen (95%CI) | I 2 Sen (95%CI) | Spe (95%CI) | I 2 Spe (95%CI) | PLR (95%CI) | NLR (95%CI) | DOR (95%CI) | AUROC (95%CI) |
| 0.39 (0.21–0.61) | 80.27 (67.25–93.30) | 0.98 (0.87–1.00) | 95.67 (93.82–97.53) | 16.6 (4.5–61.5) | 0.62 (0.46–0.85) | 27 (9–81) | 0.77 (0.73–0.80) |
| Univariable meta-regression | Multivariable meta-regression | ||||||
| Parameter | No. of study | Sen (95%CI) | P Sen | Spe (95%CI) | P Spe | I 2 (95%CI) | P I 2 |
| Stage | 0.64 | <0.001 | 0 (0–100) | 0.66 | |||
| I-IV | 5 | 0.35 (0.09–0.62) | 0.99 (0.96–1.00) | ||||
| III,IV | 3 | 0.47 (0.15–0.79) | 0.95 (0.82–1.00) | ||||
| Patient size | 0.03 | 0.07 | 62 (13–100) | 0.07 | |||
| ≥100 | 5 | 0.28 (0.12–0.45) | 0.99 (0.98–1.00) | ||||
| <100 | 3 | 0.66 (0.45–0.87) | 0.85 (0.62–1.00) | ||||
| Sampling time | 0.55 | 0.02 | 0 (0–100) | 0.68 | |||
| Before treatment | 7 | 0.37 (0.14–0.59) | 0.98 (0.93–1.00) | ||||
| After treatment | 1 | 0.51 (0.00–1.00) | 0.96 (0.81–1.00) | ||||
| Methods | 0.48 | 0.40 | 0 (0–100) | 0.79 | |||
| CLIA | 5 | 0.35 (0.11–0.58) | 0.98 (0.95–1.00) | ||||
| ELISA | 3 | 0.49 (0.15–0.84) | 0.96 (0.84–1.00) | ||||
| Ethnicity | 0.21 | <0.001 | 48 (0–100) | 0.15 | |||
| Japanese | 5 | 0.30 (0.08–0.52) | 0.99 (0.98–1.00) | ||||
| Chinese | 3 | 0.58 (0.30–0.86) | 0.88 (0.65–1.00) | ||||
Sen sensitivity; Spe specificity; PLR positive likelihood ratios; NLR negative likelihood ratios; DOR diagnostic odds ratios; AUROC area under receiver operating curve; CLIA chemiluminescence immunoassays; ELISA enzyme-linked immunosorbent assay